On this page
Marico lifts PLIX stake to 84% with ₹1,012 crore deal; remaining 14% expected in July 2027
Our read
Marico most likely completes the PLIX buyout in July 2027 at or near the ₹592 crore base, having already consolidated control at 84.09%.
Watch
Marico quarterly results showing PLIX revenue growth and margin contribution
Ask next
The report,
Marico acquired a further 24.09% of PLIX parent Satiya Nutraceuticals for ₹1,012.03 crore on October 5, lifting its holding to 84.09%. The remaining 14.09% is expected to be acquired in July 2027. Marico also expects to surpass near-term guidance.
- Marico total holding in Satiya
- 84.09%
- Additional stake acquired in Satiya
- 24.09%
- Consideration for additional stake
- ₹1,012.03 crore
- Remaining stake to be acquired
- 14.09%
Reported figures
From the report. Source details below
| Aggregate consideration for 84.09% stake: | ₹1,392.07 crore |
|---|---|
| Base consideration for remaining stake: | up to ₹592 crore |
| Stake held by founders and others: | 38.18% |
What to watch next
- Any exchange filing that changes the ₹592 crore base consideration or the July 2027 timing
- Management commentary on PLIX distribution expansion beyond D2C channels
- Marico's July 2027 filing confirming completion of the remaining 14.09%
- Fresh funding or acquisition activity among competing D2C nutrition brands
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Marico is likely to consolidate Satiya Nutraceuticals at its 84.09% holding and report PLIX as a larger contributor to its growth and margin story in coming quarters.
- Expect Marico to push PLIX through its wider distribution, including modern trade and quick-commerce, to show the ₹1,392 crore aggregate outlay is earning a return.
- Marico is likely to describe the July 2027 purchase of the remaining 14.09% as a planned step and confirm it through a stock-exchange disclosure when it closes.
- PLIX's remaining minority holders are likely to focus on growth targets that set the final consideration, up to ₹592 crore, and may lobby for the upper end of that range.
- Rival D2C and plant-based nutrition brands may step up marketing and seek strategic capital, citing Marico's bigger commitment as validation of the category.
The source
Published
Also reported by Inc42, NDTV Profit, Storyboard18, Entrackr, afaqs, The Hindu BusinessLine, BW Disrupt
First seen